Accent Therapeutics, a Lexington, MA-based biopharmaceutical company focused on small molecule precision cancer therapies, raised $75M in Series C funding.
The round was led by Mirae Asset Capital Life Science, with participation from other new investors Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb and Johnson & Johnson Innovation – JJDC, Inc., as well as all existing investors, including The Column Group, Atlas Venture, Droia Ventures, GV, EcoR1 Capital, AbbVie Ventures, The Mark Foundation for Cancer Research, Timefolio Capital (formerly known as NS Investment) and others. In conjunction with the financing, Naveen Krishnan, MD, MPhil, Managing Director of Mirae Asset Capital Life Science will join the Company’s Board of Directors.
The company intends to use the funds to advance its both lead programs –Accent’s first-in-class DHX9 inhibitor and a potentially best-in-class KIF18A inhibitor – through early clinical development including safety, pharmacokinetics and early efficacy studies.
Led by CEO Shakti Narayan, PhD, JD, Accent Therapeutics provides small molecule precision cancer therapies targeting critical intracellular dependencies that span multiple types of cancer. Building upon expertise in RNA-modifying proteins (RMPs) and the systematic mapping of both the RMP space and adjacent high-value areas for drug discovery, the company’s DHX9 inhibitor seeks to address indications with high unmet need, including BRCA loss of function cancers (breast, ovarian), mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) cancers (colorectal, endometrial, gastric) and additional undisclosed cancer types. Accent’s second lead program, a KIF18A inhibitor, could also potentially benefit a large patient population across several cancer indications with high unmet need, including ovarian cancer and triple negative breast cancer (TNBC).
FinSMEs
23/01/2024